



Uscom

ASX Media Release

CE Mark for New Uscom Asthma and COPD Devices New Uscom SpiroSonic Pulmonary Digital Monitoring Technologies Approved for European Sale

Sydney, Australia: 31st October 2016: Uscom (ASX code: UCM) (the **Company** or **Uscom**), today announced to market receipt of CE Mark for Uscom SpiroSonic digital ultrasonic technologies allowing sale of the devices into Europe, one of the 3 major medical device markets of the world. The CE Mark, while mandatory for European sales, is also often a predicate for regulatory approval in smaller regional markets.

The Uscom SpiroSonic devices are patent protected, multi-path, digital ultrasonic, pulmonary testing devices and compliment the USCOM 1A advanced haemodynamic monitor and BP+ central blood pressure monitoring technologies owned by Uscom. The Uscom SpiroSonic Flo, Smart, Mobile and Pro devices and the proprietary SpiroReporter archiving, analysis and reporting software will be manufactured at Uscom Budapest, Hungary, and the first devices were received at Uscom, Sydney last week. Uscom Budapest was acquired as a strategic acquisition for entry into the global pulmonary care market in September 2015, and is a wholly owned subsidiary of Uscom Limited employing approximately 20 people in R&D and manufacturing, with CE and FDA manufacturing accreditation.

The Uscom SpiroSonic devices are state of the art and can be wirelessly connected to a mobile device loaded with the proprietary SpiroSonic application, and can also connect to the proprietary Uscom SpiroReporter software in the cloud or on a clinic based server for central patient register, archiving, analysis and reporting. This allows for high fidelity remote tele-monitoring of asthma and chronic obstructive pulmonary disease (COPD) and replaces simple adherence monitoring and diagnostic alarm systems with research quality SpiroSonic spirometers. The Uscom devices are already being sold into the US home care market through Cohero Health, based in New York, using mobile phone connectivity to provide guidance for clinicians to choose appropriate therapy, and follow up response monitoring. Cohero have partnered with the large US Blue Cross, Blue Shield Association (BCBSA) to develop a home care asthma and COPD monitoring platform that includes the Uscom mobile spirometers. The BCBSA covers more than 106 million members in the USA, while 96% of US Hospitals and 93% of professional providers contract directly with BCBSA companies.

The updated CE mark allows Uscom to advance a number of distribution agreements in Europe. Current Uscom revenues are predominantly from USCOM 1A sales, however with the CE Mark for the 4 new SpiroSonic devices, and with impending distribution agreements, Uscom revenue opportunities are increased substantially.

Uscom is currently preparing to submit the SpiroSonic devices for FDA (USA) and CFDA (China) regulatory approval, and are talking with major monitoring companies for distribution of the Uscom SpiroSonic suite of products into the global market.

Mr Ferenczi, Uscom Global Head of Pulmonary Devices said, *“The acquisition of Thor by Uscom Australian has improved our credibility and visibility in the market and increased interest in our products. This will continue as we bring the new SpiroSonic devices to market. We previously only sold into small markets in middle Europe, while this restructure and rebranding will deliver our SpiroSonic technology to China, the US and the large distributors covering the European markets of Germany, France and Italy”*

Uscom CEO Associate Professor Rob Phillips said, *“This technology is world leading and the CE approval allows us to sell our SpiroSonic devices into the 740m strong European market. There is a growing global focus on improving asthma and COPD diagnosis,*

For personal use only



Uscom

ASX Media Release

monitoring and therapy, and this will rapidly convert into sales of our high fidelity digital ultrasonic spirometers and connected software platforms. It will be an exciting time for Uscom over the next two years as our SpiroSonic and BP+ devices are delivered to market and our distribution grows to accommodate the new global opportunities generating revenue and profit for shareholders.”

Uscom manufactures and markets the USCOM 1A advanced haemodynamic monitor, the Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometry devices. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. These products are integral for optimising management of sepsis, guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and in clinical and home care asthma and COPD monitoring.

For personal use only



Uscom

ASX Media Release

About Uscom

Uscom Limited (UCM) is an ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

The USCOM 1A is a simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

The Uscom BP+ is a supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension, heart failure, intensive care, general practice and home care.

Uscom SpiroSonic digital ultrasonic spirometers are high fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They are simple and accurate to use and provide research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone applications and proprietary SpiroSonic software platforms with wireless interfacing to provide remote tele-monitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, industrial lung disease and monitoring of pulmonary therapeutic compliance.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Associate Professor Rob Phillips
Executive Chairman
rob@uscom.com.au

Brett Crowley
Company Secretary
secretary@uscom.com.au